Pathophysiology and medical treatment of pain in fibrous dysplasia of bone
AffiliationINSERM UMR 1033, Université de Lyon, Hospices Civils de Lyon, Hôpital E Herriot, 69437 Lyon, France
National Reference Center for Fibrous Dysplasia of Bone, Hôpital E Herriot, 69437 Lyon, France
Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA
Research Service, VA Medical Center, Minneapolis, MN 55417, USA
Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
MetadataShow full item record
CitationChapurlat et al. Orphanet Journal of Rare Diseases 2012, 7(Suppl 1):S3 http://www.ojrd.com/content/7/S1/S3
Rights© 2012 Chapurlat et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)
Collection InformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at firstname.lastname@example.org.
AbstractOne of the most common complications of fibrous dysplasia of bone (FD) is bone pain. Usual pain killers are often of inadequate efficacy to control this bone pain. The mechanism of bone pain in FD remains uncertain, but by analogy with bone tumors one may consider that ectopic sprouting and formation of neuroma-like structures by sensory and sympathetic nerve fibers also occur in the dysplastic skeleton. Bone pain has been reported in up to 81% of adults and 49% of children. It affects predominantly the lower limbs and the spine. The degree of pain is highly variable and adults reports more pain than children. Bisphosphonates have been shown to reduce bone pain in uncontrolled studies. Their influence on bone strength remains unknown. In a randomized trial testing alendronate, bone pain was not significantly improved. Another trial assessing the effect of risedronate is ongoing. Possible future therapies include tocilizumab, denosumab and drugs targeting nerve growth factor and its receptor TrkA.
VersionFinal published version